Varex Imaging Corporation filings document operating results, financing agreements, governance votes and material events for an X-ray imaging component manufacturer. Recent 8-K reports furnish preliminary quarterly and fiscal-year results, including segment disclosures for the Medical and Industrial businesses and product-demand commentary for CT, cargo systems and detectors.
The company’s regulatory filings also describe its Credit and Guaranty Agreement, secured term loan, revolving credit and delayed draw term loan facilities, subsidiary guarantees, covenants and senior secured note redemption. Governance filings record annual meeting voting results, director elections, auditor ratification, executive compensation votes and officer transition arrangements.
Varex Imaging Corporation reported higher sales but a net loss for the quarter ended April 3, 2026. Revenue rose slightly to $216.0 million from $212.9 million a year earlier, with growth in the Americas and APAC partly offset by softer EMEA demand.
Operating income fell to $14.4 million from $22.1 million as gross profit declined and selling, general, and administrative costs increased. A sharp rise in interest expense, including a $9.4 million loss on debt extinguishment, pushed the company to a quarterly net loss attributable to Varex of $8.1 million, or $0.19 per diluted share, versus earnings of $6.9 million, or $0.17 per diluted share, in the prior-year quarter.
For the first six months, revenue increased to $425.6 million from $412.7 million, but Varex posted a net loss of $5.8 million compared with net income of $6.6 million a year ago. Operating cash flow swung to an outflow of $17.6 million from an inflow of $26.1 million, driven largely by higher inventories. Cash and cash equivalents declined to $85.3 million, while inventories rose to $346.7 million. The company refinanced its capital structure with a new $350.0 million term loan and $100.0 million revolving credit facility, redeeming $368.0 million of 7.875% senior secured notes.
Varex Imaging Corporation reported unaudited results for its second quarter of fiscal 2026, with revenue of $216 million, up 1% year-over-year, but a GAAP net loss. Medical revenue was $156 million and Industrial revenue was $60 million.
GAAP gross margin was 34% and GAAP operating margin 7%. The company posted a GAAP net loss of $0.19 per diluted share, while non-GAAP net income was $0.21 per diluted share, down from $0.31 a year earlier as lower margins and higher interest and other costs weighed on results.
Cash outflows from operations were $2 million. Cash, cash equivalents, and marketable securities totaled $88 million, down from $155 million at the end of fiscal 2025, mainly due to debt redemption and refinancing and higher inventory to support anticipated demand. For full fiscal 2026, Varex expects revenue between $860 million and $880 million and non-GAAP EPS between $0.80 and $1.00, with third-quarter revenue guidance of $210 million to $225 million and non-GAAP EPS of $0.15 to $0.30.
Varex Imaging Corp executive Jesse Don Merkley, SVP and GM, Industrial, filed an initial ownership report showing his equity stake in the company. He directly holds 15,334 shares of common stock as of the reported date.
He also holds several equity awards, including restricted stock units and performance stock units that each convert into common stock on a one-for-one basis as vesting and performance conditions are met. In addition, he holds a non-qualified stock option covering 9,727 shares of common stock at an exercise price of $24.55 per share, expiring in 2033, along with multiple RSU and PSU grants that vest over time and are tied to fiscal-year performance criteria.
Varex Imaging Corp ownership disclosure: The Vanguard Group filed an amended Schedule 13G/A reporting 0 shares beneficially owned of Varex Imaging Corp common stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026 that prompted disaggregated reporting by Vanguard subsidiaries. The amendment is signed by Ashley Grim on 03/27/2026.
Varex Imaging Corp senior vice president of regulatory and quality assurance Victor Hugo Garcia filed a Form 3 detailing his existing equity stake in the company. The filing shows direct ownership of 23,360 shares of common stock, along with multiple blocks of restricted stock units, performance stock units, and non-qualified stock options. These derivative awards cover underlying common shares at exercise prices ranging from $22.13 to $31.42, with option expirations extending through December 8, 2032. The entries reflect current holdings rather than new open‑market purchases or sales.
Varex Imaging Corp director Jay K. Kunkel sold shares in a routine open-market transaction. He sold 4,510 shares of common stock at a price of $11.14 per share. After this sale, he directly holds 23,450 shares, so he continues to maintain a significant equity stake in the company.
VREX submitted a Rule 144 notice relating to the sale of Common stock through Fidelity Brokerage Services LLC. The filing lists two previously vested restricted-stock items: 875 shares vested on 02/13/2023 and 3,635 shares vested on 02/11/2024900 Salem Street, Smithfield, RI and the exchange is shown as NASDAQ.
Varex Imaging Corporation has refinanced its debt by entering into a new Credit and Guaranty Agreement providing a $350 million secured term loan, a $100 million secured revolving credit facility, and a $40 million secured delayed draw term loan, for total commitments of $490 million maturing on March 13, 2031.
The company drew $350 million from the term loan and, together with about $42 million of cash, funded the redemption of $368 million of 7.875% Senior Secured Notes due 2027 and related costs. This reduced outstanding debt by $18 million and is expected to lower annual cash interest expense by more than $7 million.
Borrowings bear SOFR-based variable interest plus a margin tied to Varex’s consolidated net leverage ratio, with an interest rate swap fixing the SOFR component at 3.65% and an initial 2.50% margin. The prior $155 million revolving credit facility was terminated, and the new revolver supports working capital and general corporate purposes.
Varex Imaging Corporation reported the results of its 2026 annual meeting of stockholders. Stockholders representing 38,575,226 shares, about 92% of shares outstanding and eligible to vote, were present in person or by proxy, establishing a strong quorum.
All seven director nominees — Kathleen L. Bardwell, Jocelyn D. Chertoff, Timothy E. Guertin, Jay K. Kunkel, Walter M. Rosebrough, Jr., Sunny S. Sanyal and Christine A. Tsingos — were elected to serve until the 2027 annual meeting of stockholders.
Stockholders also approved on an advisory basis the compensation of the company’s named executive officers and ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2026.
Varex Imaging Corp director Kathleen Bardwell reported an acquisition of deferred stock units. On 02/12/2026, she received 12,331 Deferred Stock Units at a price of $0 per unit, all held as direct beneficial ownership.
Each Deferred Stock Unit converts into one share of common stock. The units vest 100% on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting after the grant date. Vested shares will be delivered upon the earlier of the third anniversary of the grant date, a change in control, or the end of Bardwell’s service for any reason.